Given that T1DM is characterized as an autoimmune disease, where immune cells attack and destroy pancreatic β -cells, it is crucial to consider the immunomodulatory properties of BMCs and their ability to differentiate into insulin-producing cells when utilizing BMT for T1DM treatment. The gene discussed is INS; the disease is autoimmune disease.